CasNo.274693-27-5,Ticagrelor,(274693-27-5) Suppliers

25 Kilogram	Negotiable

Min.Order :25 Kilogram
Purity: 99%
Payment Terms : L/C,T/T,,Other

Keywords

(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;Brilique AR-C 619-540-9

Quick Details

Appearance:white power
Application:Pharma;Industry;Agricultural;chemical reaserch
PackAge:as your requirement
ProductionCapacity:500~1000|Kilogram|Month
Storage:Keep it in dry,shady and cool place
Transportation:SEA OR AIR

Superiority:

1,we produce and sell good chemicals around the world.

2,our success rate is about 95%. this means, if customer order is accepted, the probability that the customer will obtain the ordered substances, is 95%.

3,our staff consists of highly qualified individuals with bsc, msc and ph.d degrees in chemistry, as well as excellent carbohydrates,nucleosides, small molecules and rare chemicals.

4,imaginechem's chemists are skilled at performing complex, multi-step syntheses and solving difficult chemistry-related problems. because of our better, concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery.

5,all chemicals are typically >97% for building blocks, the structure and purity is confirmed by nmr and lc-ms. intermediates and final products are analyzed by gc, hplc, ir, nmr, ms, elemental analysis, atom-absorpting analysis and crystallographical methods.

415,customers-oriented strategy, exclusive supply chain management, professional r&d team, experienced production workers, energetic sales team enable us to offer best service andgood-value products to all of our customers and gradually reach our final goals: becoming global leading supplier for portable products and solutions.

Details:

AstraZeneca (AstraZeneca) by the United States company research and development success, is the world's first reversible type combined with oral P2Y12 ADP receptor antagonist, the drug can be reversible effect on vascular smooth muscle cells (VSMC) on purine 2 receptor subtype (purinoceptor 2, P2) P2Y12, don't need metabolic activation of adenosine diphosphate (ADP) has obvious inhibitory effect on platelet aggregation, and oral use catch-up effect quickly, can effectively improve symptoms of patients with acute coronary heart disease (CHD). Unlike thiophene and pyridine class of drugs, grey for P2Y12 receptor is reversible inhibitor for card, so for those that should be carried out in the early anticoagulation therapy after surgery any patient is particularly applicable.

Astrazeneca's gray card for development since 1999, the European heart association released (ESC) 2009 annual meeting for the first time for card gray Ⅲ period test results, detailed compares the in patients with acute coronary syndrome (ACS).

In November 2009, astrazeneca, respectively, to the European Union and the United States FDA gray's new drug applications submitted for card.

For gray card approved by the European Union in December 2010, used in adult patients with acute coronary syndrome (ACS) thrombosis incident prevention of atherosclerosis.

On December 17, 2010, the United States food and drug administration (FDA) has again decided to postpone approval of astrazeneca's new antiplatelet drugs for card gray (ticagrelor), to the company required to provide a letter to the FDA to do research on platelet inhibition and the prognosis of patients with additional analysis.

In January 2011 for gray officially sold in all eu member states, commodity name Brilique, the specification is 90 mg/piece, 60 slices of pack.

On July 20, 2011, astrazeneca announced that the FDA has approved for gray card to reduce cardiovascular death in patients with acute coronary syndrome (ACS) and heart attacks.

So far for card gray has been approed for sale in 41 countries, and included in the seven countries, such as the UK medical compensation scope.